Symbols / FULC Stock $3.37 +4.66% Fulcrum Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
FULC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Alexander C. Sapir
Exch · Country NGM · United States
Market Cap 224.55M
Enterprise Value -112.89M
Income -76.12M
Sales —
FCF (ttm) -37.74M
Book/sh 5.00
Cash/sh 5.00
Employees 55
Insider 10d —
IPO Jul 18, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.50
PEG —
P/S —
P/B 0.67
P/C —
EV/EBITDA 1.32
EV/Sales —
Quick Ratio 33.97
Current Ratio 34.33
Debt/Eq 1.76
LT Debt/Eq —
EPS (ttm) -1.15
EPS next Y -0.61
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-27
Earnings (prior) 2026-04-27
ROA -18.36%
ROE -27.10%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 66.63M
Shs Float 47.97M
Insider Own 3.86%
Instit Own 108.04%
Short Float 11.84%
Short Ratio 10.71
Short Interest 7.80M
52W High 15.74
vs 52W High -78.59%
52W Low 2.83
vs 52W Low 19.08%
Beta 3.01
Impl. Vol. 2.67%
Rel Volume 3.22
Avg Volume 1.49M
Volume 4.79M
Target (mean) $6.33
Tgt Median $4.00
Tgt Low $3.00
Tgt High $18.00
# Analysts 9
Recom Hold
Prev Close $3.22
Price $3.37
Change 4.66%
About

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.33
Mean price target
2. Current target
$3.37
Latest analyst target
3. DCF / Fair value
$-10.19
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.37
Low
$3.00
High
$18.00
Mean
$6.33

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-03 down JP Morgan Overweight → Underweight —
2026-06-02 down Stifel Buy → Hold $3
2026-06-02 down Piper Sandler Overweight → Underweight $3
2026-06-02 down Truist Securities Buy → Hold $4
2026-06-02 down Leerink Partners Outperform → Market Perform $4
2026-06-02 down HC Wainwright & Co. Buy → Neutral $3
2026-01-12 init JP Morgan — → Overweight $20
2025-12-11 main Truist Securities Buy → Buy $18
2025-12-09 main B of A Securities Underperform → Underperform $7
2025-12-08 main RBC Capital Sector Perform → Sector Perform $10
2025-12-08 main Cantor Fitzgerald Overweight → Overweight $24
2025-12-08 reit Piper Sandler Overweight → Overweight $23
2025-12-08 main HC Wainwright & Co. Buy → Buy $25
2025-11-24 init Truist Securities — → Buy $14
2025-11-24 main HC Wainwright & Co. Buy → Buy $18
2025-10-30 main RBC Capital Sector Perform → Sector Perform $7
2025-10-30 reit Piper Sandler Overweight → Overweight $16
2025-10-20 reit HC Wainwright & Co. Buy → Buy $12
2025-07-30 main RBC Capital Sector Perform → Sector Perform $5
2025-07-29 up HC Wainwright & Co. Neutral → Buy $12
News
RSS: Latest FULC news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-02 GOULD ROBERT J. Director — 15,000 $10.72 $160,857
2026-01-02 GOULD ROBERT J. Director — 15,000 $11.87 $178,089
2026-01-02 GOULD ROBERT J. Director — 15,000 $10.87 $163,089
2025-12-15 OLTMANS CURTIS GALE Officer — 3,452 $12.92 $44,600
2025-12-08 RA CAPITAL HEALTHCARE FUND,L.P. Beneficial Owner of more than 10% of a Class of Security — 4,175,139 $13.33 $58,377,021
2025-11-19 GOULD ROBERT J. Director — 15,000 $11.03 $165,495
2025-05-08 TOURANGEAU GREG Officer — 498 $5.06 $2,520
2024-07-03 SAPIR ALEX Chief Executive Officer — 150,000 $3.27 $490,500
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
80.00
+2752.05%
2.81
-55.77%
6.34
Operating Revenue
0.00
-100.00%
80.00
+2752.05%
2.81
-55.77%
6.34
Operating Expense
84.77
-15.09%
99.83
-12.02%
113.47
-4.23%
118.48
Research And Development
56.10
-11.49%
63.39
-11.72%
71.80
-6.49%
76.78
Selling General And Administration
28.67
-21.35%
36.45
-12.53%
41.67
-0.06%
41.69
General And Administrative Expense
28.67
-21.35%
36.45
-12.53%
41.67
-0.06%
41.69
Salaries And Wages
17.33
-12.28%
19.75
-20.38%
24.81
+5.62%
23.49
Other Gand A
11.34
-32.08%
16.69
-0.98%
16.86
-7.40%
18.21
Total Expenses
84.77
-15.09%
99.83
-12.02%
113.47
-4.23%
118.48
Operating Income
-84.77
-327.39%
-19.83
+82.08%
-110.66
+1.31%
-112.13
Total Operating Income As Reported
-84.77
-287.13%
-21.90
+80.21%
-110.66
+1.69%
-112.56
EBITDA
-83.38
-357.10%
-18.24
+83.19%
-108.49
+1.12%
-109.72
Normalized EBITDA
-83.38
-415.39%
-16.18
+85.09%
-108.49
+0.73%
-109.29
Reconciled Depreciation
1.39
-12.74%
1.59
-26.66%
2.17
-10.02%
2.41
EBIT
-84.77
-327.39%
-19.83
+82.08%
-110.66
+1.31%
-112.13
Total Unusual Items
0.00
+100.00%
-2.06
0.00
+100.00%
-0.43
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-2.06
0.00
+100.00%
-0.43
Special Income Charges
0.00
+100.00%
-2.06
0.00
+100.00%
-0.43
Restructuring And Mergern Acquisition
0.00
-100.00%
2.06
0.00
-100.00%
0.43
Net Income
-74.88
-669.97%
-9.72
+90.01%
-97.33
+11.41%
-109.87
Pretax Income
-74.88
-669.97%
-9.72
+90.01%
-97.33
+11.41%
-109.87
Other Income Expense
9.89
-2.18%
10.11
-24.16%
13.33
+489.00%
2.26
Other Non Operating Income Expenses
9.89
-18.76%
12.17
-8.68%
13.33
+395.50%
2.69
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-74.88
-669.97%
-9.72
+90.01%
-97.33
+11.41%
-109.87
Net Income From Continuing Operation Net Minority Interest
-74.88
-669.97%
-9.72
+90.01%
-97.33
+11.41%
-109.87
Net Income From Continuing And Discontinued Operation
-74.88
-669.97%
-9.72
+90.01%
-97.33
+11.41%
-109.87
Net Income Continuous Operations
-74.88
-669.97%
-9.72
+90.01%
-97.33
+11.41%
-109.87
Normalized Income
-74.88
-877.29%
-7.66
+92.13%
-97.33
+11.06%
-109.44
Net Income Common Stockholders
-74.88
-669.97%
-9.72
+90.01%
-97.33
+11.41%
-109.87
Diluted EPS
-1.18
-637.50%
-0.16
+89.94%
-1.59
+34.84%
-2.44
Basic EPS
-1.18
-637.50%
-0.16
+89.94%
-1.59
+34.84%
-2.44
Basic Average Shares
63.35
+2.21%
61.98
+1.10%
61.31
+36.27%
44.99
Diluted Average Shares
63.35
+2.21%
61.98
+1.10%
61.31
+36.27%
44.99
Diluted NI Availto Com Stockholders
-74.88
-669.97%
-9.72
+90.01%
-97.33
+11.41%
-109.87
Line Item Trend 2023-12-31
Total Assets
257.69
Current Assets
242.20
Cash Cash Equivalents And Short Term Investments
236.22
Cash And Cash Equivalents
25.56
Cash Equivalents
25.56
Other Short Term Investments
210.66
Receivables
2.25
Accounts Receivable
—
Other Receivables
0.54
Accrued Interest Receivable
1.71
Prepaid Assets
3.73
Total Non Current Assets
15.49
Net PPE
12.39
Gross PPE
25.15
Accumulated Depreciation
-12.76
Properties
0.00
Machinery Furniture Equipment
1.19
Construction In Progress
0.00
Other Properties
16.86
Leases
7.10
Other Non Current Assets
3.10
Total Liabilities Net Minority Interest
22.50
Current Liabilities
13.68
Payables And Accrued Expenses
11.09
Payables
2.76
Accounts Payable
2.76
Current Accrued Expenses
8.33
Current Debt And Capital Lease Obligation
2.19
Current Capital Lease Obligation
2.19
Current Deferred Liabilities
0.00
Current Deferred Revenue
0.00
Other Current Liabilities
0.40
Total Non Current Liabilities Net Minority Interest
8.83
Long Term Debt And Capital Lease Obligation
8.63
Long Term Capital Lease Obligation
8.63
Non Current Deferred Liabilities
—
Non Current Deferred Revenue
—
Other Non Current Liabilities
0.20
Stockholders Equity
235.19
Common Stock Equity
235.19
Capital Stock
0.06
Common Stock
0.06
Preferred Stock
0.00
Share Issued
61.92
Ordinary Shares Number
61.92
Treasury Shares Number
0.00
Additional Paid In Capital
744.94
Retained Earnings
-509.67
Gains Losses Not Affecting Retained Earnings
-0.14
Treasury Stock
—
Other Equity Adjustments
-0.14
Total Equity Gross Minority Interest
235.19
Total Capitalization
235.19
Working Capital
228.52
Invested Capital
235.19
Total Debt
10.82
Capital Lease Obligations
10.82
Net Tangible Assets
235.19
Tangible Book Value
235.19
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-60.06
-2608.07%
-2.22
+97.56%
-90.97
+6.27%
-97.05
Cash Flow From Continuing Operating Activities
-60.06
-2608.07%
-2.22
+97.56%
-90.97
+6.27%
-97.05
Net Income From Continuing Operations
-74.88
-669.97%
-9.72
+90.01%
-97.33
+11.41%
-109.87
Depreciation Amortization Depletion
1.39
-12.74%
1.59
-26.66%
2.17
-10.02%
2.41
Depreciation
1.39
-12.74%
1.59
-26.66%
2.17
-10.02%
2.41
Depreciation And Amortization
1.39
-12.74%
1.59
-26.66%
2.17
-10.02%
2.41
Stock Based Compensation
12.47
-14.33%
14.55
-1.68%
14.80
+10.88%
13.35
Change In Working Capital
3.91
+192.04%
-4.25
+7.91%
-4.61
-49.10%
-3.09
Change In Receivables
2.10
+234.45%
-1.56
-406.17%
-0.31
-109.04%
3.41
Changes In Account Receivables
—
—
0.00
-100.00%
2.50
Change In Prepaid Assets
1.63
+219.56%
-1.36
-27.33%
-1.07
-530.59%
-0.17
Change In Payables And Accrued Expense
1.45
+155.35%
-2.62
-56.44%
-1.68
-170.21%
-0.62
Change In Accrued Expense
1.02
+199.32%
-1.03
-25.09%
-0.82
-248.65%
0.56
Change In Payable
0.43
+126.87%
-1.59
-86.75%
-0.85
+27.47%
-1.18
Change In Account Payable
0.43
+126.87%
-1.59
-86.75%
-0.85
+27.47%
-1.18
Change In Other Working Capital
-0.74
-6.14%
-0.70
+57.55%
-1.65
+60.26%
-4.15
Change In Other Current Assets
-0.53
-126.39%
2.00
+2028.72%
0.09
+106.02%
-1.56
Investing Cash Flow
30.72
-4.69%
32.23
+187.84%
-36.69
-395.59%
12.41
Cash Flow From Continuing Investing Activities
30.72
-4.69%
32.23
+187.84%
-36.69
-395.59%
12.41
Net PPE Purchase And Sale
-0.31
-12.95%
-0.28
+45.28%
-0.51
+74.12%
-1.96
Purchase Of PPE
-0.31
-12.95%
-0.28
+45.28%
-0.51
+74.12%
-1.96
Capital Expenditure
-0.31
-12.95%
-0.28
+45.28%
-0.51
+74.12%
-1.96
Net Investment Purchase And Sale
31.03
-4.54%
32.51
+189.84%
-36.18
-351.70%
14.38
Purchase Of Investment
-180.22
-0.91%
-178.59
+8.36%
-194.89
-28.94%
-151.15
Sale Of Investment
211.25
+0.07%
211.10
+33.01%
158.71
-4.12%
165.53
Financing Cash Flow
168.67
+6042.28%
2.75
-97.68%
118.12
+40.08%
84.32
Cash Flow From Continuing Financing Activities
168.67
+6042.28%
2.75
-97.68%
118.12
+40.08%
84.32
Net Issuance Payments Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
164.50
0.00
-100.00%
117.34
+45.22%
80.80
Proceeds From Stock Option Exercised
4.17
+51.75%
2.75
+253.41%
0.78
-77.92%
3.52
Changes In Cash
139.32
+325.30%
32.76
+443.56%
-9.54
-2936.62%
-0.31
Beginning Cash Position
59.41
+122.90%
26.66
-26.35%
36.19
-0.86%
36.50
End Cash Position
198.73
+234.50%
59.41
+122.90%
26.66
-26.35%
36.19
Free Cash Flow
-60.38
-2319.03%
-2.50
+97.27%
-91.47
+7.62%
-99.01
Interest Paid Supplemental Data
—
—
—
—
Amortization Of Securities
-2.95
+32.76%
-4.39
+26.69%
-5.99
-4041.45%
0.15
Common Stock Issuance
164.50
0.00
-100.00%
117.34
+45.22%
80.80
Issuance Of Capital Stock
164.50
0.00
-100.00%
117.34
+45.22%
80.80
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category